3,5-dibromo-4-methyl-thiophene-2-carboxylic acid | 856354-09-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 3,5-dibromo-4-methyl-thiophene-2-carboxylic acid
• 英文别名: 3,5-Dibrom-4-methyl-thiophen-2-carbonsaeure；3,5-Dibromo-4-methylthiophene-2-carboxylic acid
• CAS: 856354-09-1
• 化学式: C₆H₄Br₂O₂S
• 分子量: 299.971
• InChiKey: FCFZMWHMDWYVTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3,5-dibromo-4-methyl-thiophene-2-carboxylic acid 在 溶剂黄146 、 sodium chloride 、 mercury(II) oxide 作用下， 生成 2,4,-二溴-3-甲基噻吩
  参考文献：
  名称：

  Steinkopf; Nitschke, Justus Liebigs Annalen der Chemie, 1938, vol. 536, p. 135,142

  摘要：

  DOI：
• 作为产物：
  描述：

  3-溴-4-甲基噻吩-2-羧酸甲酯 在 sodium hydroxide 、 溴 作用下， 生成 3,5-dibromo-4-methyl-thiophene-2-carboxylic acid
  参考文献：
  名称：

  Steinkopf; Nitschke, Justus Liebigs Annalen der Chemie, 1938, vol. 536, p. 135,142

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED THIOPHENE CARBOXAMIDES, THIOPHENE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF<br/>[FR] THIOPHÈNE CARBOXAMIDES SUBSTITUÉS, ACIDES THIOPHÈNE CARBOXYLIQUES ET LEURS DÉRIVÉS
  申请人：BAYER AG

  公开号：WO2021123051A1

  公开（公告）日：2021-06-24

  The present disclosure relates to substituted thiophene carboxamides derivatives of formula (I) adn (II), their use for controlling phytopathogenic microorganisms and compositions comprising thereof.

  本公开涉及公式(I)和(II)的取代噻吩羧酰胺衍生物，其用于控制植物病原微生物以及包含它们的组合物。
• COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20130190289A1

  公开（公告）日：2013-07-25

  A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

  一种化合物由结构式(I)或其药学上可接受的盐所代表，其中结构式(I)的变量如规范和权利要求所描述。一种药物组合物包括一种由结构式(I)或其药学上可接受的盐所代表的化合物，以及药学上可接受的载体或赋形剂。一种治疗HCV感染的方法包括向受试者施用一种由结构式(I)或其药学上可接受的盐所代表的治疗有效量的化合物。一种抑制或减少受试者或生物体外样本中HCV聚合酶活性的方法包括向受试者或样本中施用一种由结构式(I)或其药学上可接受的盐所代表的治疗有效量的化合物。
• PROCESS FOR PREPARING 3-(SUBSTITUTED PHENYL)-5-THIENYL OR FURYL)-1,2,4-TRIAZOLES AND NOVEL INTERMEDIATES UTILIZED THEREIN
  申请人：Dow Agrosciences LLC

  公开号：EP1123291A1

  公开（公告）日：2001-08-16
• [EN] PROCESS FOR PREPARING 3-(SUBSTITUTED PHENYL)-5-THIENYL OR FURYL)-1,2,4-TRIAZOLES AND NOVEL INTERMEDIATES UTILIZED THEREIN<br/>[FR] PROCEDE DE PREPARATION DE 3-(PHENYLE SUBSTITUE)-5-(THIENYLE OU FURYLE)-1,2,4-TRIAZOLES ET INTERMEDIAIRES UTILISES PAR CES DERNIERS
  申请人：DOW AGROSCIENCES LLC

  公开号：WO2000024738A1

  公开（公告）日：2000-05-04

  New synthetic procedures for preparing insecticidal 3-(substituted phenyl)-5-(thienyl or furyl)-1,2,4-triazoles utilizing thioimidate intermediate.
• [EN] COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT OU LA PRÉVENTION D'INFECTIONS PAR FLAVIVIRUS
  申请人：VERTEX PHARMA

  公开号：WO2012006055A2

  公开（公告）日：2012-01-12

  A compound is represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.